Stocks and Investing Stocks and Investing
Thu, February 16, 2023

Colin Bristow Maintained (BIIB) at Strong Buy with Increased Target to $340 on, Feb 16th, 2023


Published on 2024-10-28 01:41:14 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $337 to $340 on, Feb 16th, 2023.

Colin has made no other calls on BIIB in the last 4 months.



There are 9 other peers that have a rating on BIIB. Out of the 9 peers that are also analyzing BIIB, 4 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Steve Chesney of "Atlantic Equities" Maintained at Hold with Increased Target to $295 on, Thursday, December 1st, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Increased Target to $313 on, Wednesday, November 30th, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $247 on, Wednesday, November 30th, 2022
  • Yatin Suneja of "Guggenheim" Maintained at Hold with Increased Target to $270 on, Friday, November 11th, 2022


These are the ratings of the 5 analyists that currently disagree with Colin


  • Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, November 30th, 2022
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $350 on, Tuesday, November 15th, 2022
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $325 on, Tuesday, November 1st, 2022
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $370 on, Wednesday, October 26th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $310 on, Wednesday, October 26th, 2022

Contributing Sources